{"schema_version":"secwatch.filing_event.v1","accession":"0000310764-22-000008","form_type":"8-K","ticker":"SYK","cik":"0000310764","company_name":"STRYKER CORP","filed_at":"2022-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.205111+00:00","generated_at":"2026-06-27T15:06:45.937335+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Stryker Q4 sales $4.7B (+10.3%), FY21 adj. EPS $9.09 (+22.3%); forecasts FY22 adj. EPS $9.60-10.00","bullets":["Q4 net sales $4.7B, +10.3% YoY; organic +9.0% vs 2020, +6.2% vs 2019.","Q4 reported EPS $1.73 (+16.1%); adjusted EPS $2.71 (-3.6%) year-over-year.","Full-year net sales $17.1B, +19.2% YoY; reported EPS $5.21 (+24.0%); adjusted EPS $9.09 (+22.3%).","MedSurg & Neurotech FY organic sales +13.1%; Orthopaedics & Spine FY organic +12.0%.","2022 outlook: organic sales growth 6%-8%; adjusted EPS $9.60-$10.00; expects ~1% price headwind."],"urls":{"canonical":"https://secwatch.observer/filing/0000310764-22-000008","json":"https://secwatch.observer/filing/0000310764-22-000008.json","markdown":"https://secwatch.observer/filing/0000310764-22-000008.md","text":"https://secwatch.observer/filing/0000310764-22-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310764/000031076422000008/0000310764-22-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310764/000031076422000008/syk-20220127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T15:06:45.937335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}